Health care stocks were softer late Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing 0.2%.
The iShares Biotechnology ETF (IBB) shed 0.6%.
In corporate news, Chimerix (CMRX) shares soared 224% a day after the company said it plans to submit a new drug application with the US Food and Drug Administration seeking accelerated approval for dordaviprone.
UniQure (QURE) shares surged 110% after Wells Fargo upgraded the company's stock to overweight from equalweight, with a $35 price target. The upgrade follows the company's announcement that it reached an agreement with the US Food and Drug Administration on elements of an accelerated approval pathway for its drug AMT-130, a potential treatment for Huntington's disease.
Walgreens Boots Alliance (WBA) shares surged 16%. The company is in talks to be acquired by private equity firm Sycamore Partners, The Wall Street Journal reported, citing people familiar with the matter.
CervoMed (CRVO) shares plunged 78% after the company said a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.